Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...
The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...
VS Code is a popular choice because it’s free, flexible with lots of extensions, and has built-in Git support, making it a ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...
A Country Programme Framework (CPF), prepared by a Member State in collaboration with the Secretariat, defines mutually agreed priority development needs and interests to be supported through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback